Direct Probing of Germinal Center Responses Reveals Immunological Features and Bottlenecks for Neutralizing Antibody Responses to HIV Env Trimer.

PubWeight™: 0.81‹?›

🔗 View Article (PMID 27880897)

Published in Cell Rep on November 22, 2016

Authors

Colin Havenar-Daughton1, Diane G Carnathan2, Alba Torrents de la Peña3, Matthias Pauthner4, Bryan Briney4, Samantha M Reiss1, Jennifer S Wood5, Kirti Kaushik1, Marit J van Gils3, Sandy L Rosales6, Patricia van der Woude3, Michela Locci1, Khoa M Le4, Steven W de Taeye3, Devin Sok4, Ata Ur Rasheed Mohammed7, Jessica Huang7, Sanjeev Gumber5, AnaPatricia Garcia5, Sudhir P Kasturi8, Bali Pulendran9, John P Moore10, Rafi Ahmed11, Grégory Seumois6, Dennis R Burton12, Rogier W Sanders13, Guido Silvestri9, Shane Crotty14

Author Affiliations

1: Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA; Scripps Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, La Jolla, CA 92037, USA.
2: Scripps Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, La Jolla, CA 92037, USA; Yerkes National Primate Research Center, Emory University, Atlanta, GA 30322, USA.
3: Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, the Netherlands.
4: Scripps Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, La Jolla, CA 92037, USA; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA.
5: Yerkes National Primate Research Center, Emory University, Atlanta, GA 30322, USA.
6: Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA.
7: Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30322, USA.
8: Yerkes National Primate Research Center, Emory University, Atlanta, GA 30322, USA; Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30322, USA.
9: Scripps Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, La Jolla, CA 92037, USA; Yerkes National Primate Research Center, Emory University, Atlanta, GA 30322, USA; Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30322, USA.
10: Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, NY 10065, USA.
11: Scripps Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, La Jolla, CA 92037, USA; Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30322, USA.
12: Scripps Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, La Jolla, CA 92037, USA; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
13: Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, the Netherlands; Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, NY 10065, USA.
14: Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA; Scripps Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, La Jolla, CA 92037, USA; Department of Medicine, Division of Infectious Diseases, University of California, San Diego, La Jolla, CA 92037, USA. Electronic address: shane@lji.org.

Articles cited by this

Follicular helper CD4 T cells (TFH). Annu Rev Immunol (2011) 12.50

Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature (2011) 11.07

Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. Science (2009) 9.22

Germinal centers. Annu Rev Immunol (2012) 6.26

Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science (2013) 5.53

Germinal center dynamics revealed by multiphoton microscopy with a photoactivatable fluorescent reporter. Cell (2010) 5.49

Correlates of protection induced by vaccination. Clin Vaccine Immunol (2010) 5.21

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis (1996) 5.14

Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science (2013) 4.61

The role of antibodies in HIV vaccines. Annu Rev Immunol (2010) 4.50

A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog (2013) 4.23

Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. Immunity (2013) 3.72

Different B cell populations mediate early and late memory during an endogenous immune response. Science (2011) 3.63

Early commitment of naïve human CD4(+) T cells to the T follicular helper (T(FH)) cell lineage is induced by IL-12. Immunol Cell Biol (2009) 3.51

Multiple layers of B cell memory with different effector functions. Nat Immunol (2009) 3.33

Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci U S A (2012) 3.30

T follicular helper cell differentiation, function, and roles in disease. Immunity (2014) 3.29

Antibodies in HIV-1 vaccine development and therapy. Science (2013) 3.13

Broadly neutralizing antiviral antibodies. Annu Rev Immunol (2013) 2.77

CD4 T follicular helper cell dynamics during SIV infection. J Clin Invest (2012) 2.55

HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science (2015) 2.26

A dynamic T cell-limited checkpoint regulates affinity-dependent B cell entry into the germinal center. J Exp Med (2011) 1.97

Class-switched memory B cells remodel BCRs within secondary germinal centers. Nat Immunol (2015) 1.90

Antibody responses to envelope glycoproteins in HIV-1 infection. Nat Immunol (2015) 1.82

HIV antibodies. Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies. Science (2014) 1.81

Complex Antigens Drive Permissive Clonal Selection in Germinal Centers. Immunity (2016) 1.66

Functional STAT3 deficiency compromises the generation of human T follicular helper cells. Blood (2012) 1.62

Distinct cellular pathways select germline-encoded and somatically mutated antibodies into immunological memory. J Exp Med (2012) 1.61

Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J Exp Med (2014) 1.59

Activin A programs the differentiation of human TFH cells. Nat Immunol (2016) 1.45

Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer. Science (2016) 1.36

QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. Vaccine (2001) 1.35

Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design. Annu Rev Immunol (2016) 1.34

Human immunodeficiency virus type 1 env trimer immunization of macaques and impact of priming with viral vector or stabilized core protein. J Virol (2008) 1.32

IL-12 receptor β1 deficiency alters in vivo T follicular helper cell response in humans. Blood (2013) 1.31

Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes. Cell (2015) 1.20

A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. Nature (2016) 1.20

Clinical experience with hepatitis B vaccines. Am J Infect Control (1989) 1.12

HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen. Science (2016) 1.10

Fine-needle aspiration cytology in the diagnosis of superficial lymphadenopathy: an analysis of 2,418 cases. Diagn Cytopathol (1996) 1.04

Quality and quantity of TFH cells are critical for broad antibody development in SHIVAD8 infection. Sci Transl Med (2015) 1.03

Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity. J Virol (2015) 1.01

Visualizing antibody affinity maturation in germinal centers. Science (2016) 1.01

CXCL13 is a plasma biomarker of germinal center activity. Proc Natl Acad Sci U S A (2016) 0.99

Fine-needle aspiration (FNA) biopsy: historical aspects. Folia Histochem Cytobiol (2009) 0.97

Early preservation of CXCR5+ PD-1+ helper T cells and B cell activation predict the breadth of neutralizing antibody responses in chronic HIV-1 infection. J Virol (2014) 0.95

Early lymphoid responses and germinal center formation correlate with lower viral load set points and better prognosis of simian immunodeficiency virus infection. J Immunol (2014) 0.94

HIV-Host Interactions: Implications for Vaccine Design. Cell Host Microbe (2016) 0.93

A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses (2000) 0.92

A Cytokine-Independent Approach To Identify Antigen-Specific Human Germinal Center T Follicular Helper Cells and Rare Antigen-Specific CD4+ T Cells in Blood. J Immunol (2016) 0.92

Structure-Guided Redesign Increases the Propensity of HIV Env To Generate Highly Stable Soluble Trimers. J Virol (2015) 0.91

Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance. J Virol (1999) 0.90

Analysis of immunoglobulin transcripts and hypermutation following SHIV(AD8) infection and protein-plus-adjuvant immunization. Nat Commun (2015) 0.89

Cytokine-Independent Detection of Antigen-Specific Germinal Center T Follicular Helper Cells in Immunized Nonhuman Primates Using a Live Cell Activation-Induced Marker Technique. J Immunol (2016) 0.86

Animal models in HIV-1 protection and therapy. Curr Opin HIV AIDS (2015) 0.83

HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies. Expert Rev Vaccines (2016) 0.82

Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens. J Immunol (2016) 0.82

Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination. Proc Natl Acad Sci U S A (2016) 0.81

Immunogen design to focus the B-cell repertoire. Curr Opin HIV AIDS (2014) 0.78

Fine-Needle Aspiration Biopsy of the Lymph Node: A Novel Tool for the Monitoring of Immune Responses after Skin Antigen Delivery. J Immunol (2015) 0.76

Serial study of lymph node cell subsets using fine needle aspiration in pigtail macaques. J Immunol Methods (2013) 0.76